SLC18A3 and Alzheimer disease: AChE binding is lower in AD patients than in healthy controls, in parallel with VAChT reduction, and is further decreased by treatment with AChE inhibitors donepezil, rivastigmine and galantamine (Kuhl et al., 1999, 2000; Shinotoh et al., 2001; Kaasinen et al., 2002; Kadir et al., 2008).